DrugBiological
Oleclumab clinical trials
Also written MEDI9447.
- studies test it
- 19
- open now
- 3
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the oleclumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 14
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 11
AstraZeneca (5) · MedImmune LLC (3) · University Health Network, Toronto (3) · Jules Bordet Institute (2) · M.D. Anderson Cancer Center (2) · Assistance Publique Hopitaux De Marseille (1) · National Cancer Institute (NCI) (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Durvalumab (13) · Monalizumab (6) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Ceralasertib (2) · Danvatirsen (1) · Vistusertib (1)
Studies
Open first, then newest update. How each study uses oleclumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Oleclumab
- Durvalumab and Oleclumab in Resectable PDACRecruitingPhase 2University Health Network, TorontoNCT06060405Written as Oleclumab
- The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2Not yet recruitingPhase 2Montefiore Medical CenterNCT07146230Written as Oleclumab
- Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active, not recruitingPhase 2Jules Bordet InstituteNCT03875573Written as Oleclumab
- Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04940286Written as Oleclumab
- Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCActive, not recruitingPhase 1/2Jules Bordet InstituteNCT03616886Written as MEDI9447
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04668300Written as Oleclumab
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 3AstraZenecaNCT05221840Written as Oleclumab
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingPhase 2AstraZenecaNCT06606847Written as Oleclumab
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as Oleclumab
- Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialCompletedPhase 1National Cancer Institute (NCI)NCT03801902Written as Oleclumab
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedPhase 2MedImmune LLCNCT03822351Written as Durvalumab + Oleclumab
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440Written as Oleclumab (MEDI9447)
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedPhase 1/2MedImmune LLCNCT03611556Written as Oleclumab
- A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)CompletedPhase 1Dana-Farber Cancer InstituteNCT03773666Written as Oleclumab
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.CompletedPhase 1MedImmune LLCNCT04261075Written as oleclumab
- A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONWithdrawnPhase 2University Health Network, TorontoNCT04262375Written as Oleclumab
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnPhase 2University Health Network, TorontoNCT04262388Written as Oleclumab
- A Phase I Study of MEDI9447 (Oleclumab) in Japanese PatientsCompletedPhase 1AstraZenecaNCT03736473Written as MEDI9447 (oleclumab)
Given in every arm · 8 — oleclumab is usual care beside what is tested
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingPhase 1/2MedImmune LLCNCT03381274Written as Oleclumab
- COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCActive, not recruitingPhase 1/2MedImmune LLCNCT04068610Written as Oleclumab
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Written as Oleclumab
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingPhase 1AstraZenecaNCT03819465Written as Oleclumab
- An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerCompletedPhase 2AstraZenecaNCT04089553Written as Oleclumab
- MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedPhase 1MedImmune LLCNCT02503774Written as Oleclumab
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT02740985Written as Oleclumab
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedPhase 2MedImmune LLCNCT03794544Written as Oleclumab
Codes
What other systems call oleclumab · ClinicalTrials.gg INT015060
- UNII (FDA) 5CRY01URYQOLECLUMABConfirmed FDA, Wikidata
- Wikidata Q47123037oleclumabConfirmed FDA, Wikidata
- NCI Thesaurus C123914OleclumabOne source FDA
- DrugBank DB15088One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5CRY01URYQ | OLECLUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q47123037 | oleclumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C123914 | Oleclumab | One source FDA |
| DrugBank | DB15088 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.